Gevorg Tamamyan: Happy Birthday OncoDaily

FDA Grants Approval for Oral Decitabine/Cedazuridine with Venetoclax in Newly Diagnosed AML

How I Treat Bladder Cancer in 2026: OncoDaily Virtual Summit

Herbert Loong Invites to Attend the Sarcoma Grand Rounds at ASCO 2026

OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition

ASCO 2026 with OncoDaily: Yvonne Awards, AI in Oncology, Grand Rounds and Live Coverage from Chicago

Grand Rounds by OncoDaily: AI in Oncology Edition

Episode 15: Global Health Dialogues with Princess Dina and Dr Garo Armen

Calculators

Body Mass Index (BMI)

Cockcroft-Gault Creatinine Clearance Calculator

BSA Calculator – Body Surface Area

Carboplatin Dose Calculator (Calvert Formula)

Child-Pugh Score Calculator

ECOG Score Calculator

IBW / Adjusted Body Weight (Devine Formula)

Bone Scan Index (BSI) Tracker

Khorana Score (Cancer-Associated VTE Risk)

MASCC Risk Index Calculator (Febrile Neutropenia)

IMDC Risk Score Calculator (Metastatic RCC)

Oncotype DX Recurrence Score (RS) Categorizer

Cisplatin Cumulative Dose Toxicity Tracker

MASCC Risk Index Calculator (Febrile Neutropenia)

Identify low-risk febrile neutropenia patients using the MASCC (Multinational Association for Supportive Care in Cancer) risk index.

Check if YES (0 points), leave unchecked if NO (+5 points)

Check if YES (0 points), leave unchecked if NO (+4 points)

Check if YES (0 points), leave unchecked if NO (+3 points)

Check if YES (+3 points), leave unchecked if NO (0 points)

Check if YES (+2 points), leave unchecked if NO (0 points)

MASCC Risk Index Scoring:

  • Burden of illness: No/mild = 5, Moderate = 3, Severe = 0
  • No hypotension: +5 points
  • No COPD: +4 points
  • No dehydration: +3 points
  • Solid tumor/no fungal infection: +4 points
  • Outpatient at onset: +3 points
  • Age <60 years: +2 points

Risk Classification:

  • Low risk: ≥21 points (suitable for outpatient management)
  • High risk: <21 points (requires inpatient management)